Nephrosclerosis disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: NPH010 MIFTS: 50	Nephrosclerosis Categories: Cardiovascular diseases, Nephrological diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Nephrosclerosis

MalaCards integrated aliases for Nephrosclerosis:

Name: Nephrosclerosis ¹² ⁷⁴ ²⁰ ⁵⁴ ⁴⁴ ¹⁵ ¹⁷ ⁷¹

Renal Sclerosis ¹²

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Cardiovascular diseases Nephrological diseases

See all MalaCards categories (disease lists)

ICD10: ³²

Diseases of the circulatory system

Hypertensive diseases

Hypertensive renal disease

External Ids:

Disease Ontology ¹² DOID:11664

ICD9CM ³⁴ 587

MeSH ⁴⁴ D009400

SNOMED-CT ⁶⁷ 194773000

ICD10 ³² I12

EFO ¹⁷ EFO_1000041

UMLS ⁷¹ C0027719

Sources

Summaries for Nephrosclerosis

MalaCards based summary : Nephrosclerosis, also known as renal sclerosis, is related to malignant hypertension and proteinuria, chronic benign. An important gene associated with Nephrosclerosis is ACE (Angiotensin I Converting Enzyme), and among its related pathways/superpathways are TGF-Beta Pathway and p70S6K Signaling. The drugs Angiotensin II and Valsartan have been mentioned in the context of this disorder. Affiliated tissues include kidney, pituitary and endothelial, and related phenotypes are cardiovascular system and homeostasis/metabolism

Wikipedia : ⁷⁴ Hypertensive kidney disease is a medical condition referring to damage to the kidney due to chronic high... more...

Sources

Related Diseases for Nephrosclerosis

Diseases related to Nephrosclerosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 365)

#	Related Disease	Score	Top Affiliating Genes
1	malignant hypertension	31.1	AGTR1 ADAMTS13 ACE
2	proteinuria, chronic benign	30.8	VEGFA SYNPO NPHS2 NPHS1 AGTR1 ACE
3	hypertensive nephropathy	30.7	VEGFA AGTR1 ACE
4	pyelonephritis	30.6	TNF CCL2 ACE
5	nephrotic syndrome	30.6	SYNPO NPHS2 NPHS1 ACE
6	microvascular complications of diabetes 3	30.4	TGFB1 NPHS1 INS CCN2 AGTR1 ACE
7	uremia	30.4	TNF INS ACE
8	glomerulonephritis	30.4	TGFB1 NPHS2 NPHS1 MPO CCN2 CCL2
9	rapidly progressive glomerulonephritis	30.3	TGFB1 NPHS1 MPO
10	arteriosclerosis	30.3	INS HIF1A F3 CCL2 ACE
11	hypertensive heart disease	30.2	NR3C2 AGTR1 ACE
12	thrombotic microangiopathy	30.2	VEGFA F3 ADAMTS13
13	iga glomerulonephritis	30.1	TGFB1 NPHS2 NPHS1 CCL2 AGTR1 ACE
14	vesicoureteral reflux 1	30.0	TGFB1 AGTR1 ACE
15	brucellosis	29.9	TNF TGFB1 MPO
16	focal segmental glomerulosclerosis	29.9	TNF TGFB1 SYNPO NPHS2 NPHS1 CCL2
17	end stage renal disease	29.9	VEGFA TNF TGFB1 NPHS2 NPHS1 MTHFR
18	pulmonary edema	29.8	TNF HIF1A AGTR1 ACE
19	proteasome-associated autoinflammatory syndrome 1	29.8	TNF MPO INS CCL2
20	membranous nephropathy	29.7	TNF NPHS2 NPHS1 MPO ACE
21	systemic scleroderma	29.7	TNF TGFB1 INS CCN2 ACE
22	ureteral obstruction	29.7	TGFB1 NR3C2 BMP7 AGTR1
23	deficiency anemia	29.6	TNF INS HIF1A ADAMTS13 ACE
24	peripheral vascular disease	29.6	VEGFA MTHFR F3 CCL2 ACE
25	disseminated intravascular coagulation	29.6	TNF F3 ADAMTS13
26	renal hypertension	29.6	NR3C2 NPHS1 AGTR1 ACE2 ACE
27	microvascular complications of diabetes 5	29.5	VEGFA INS HIF1A CCN2 AGTR1 ACE
28	hypertensive retinopathy	29.5	VEGFA NR3C2 AGTR1 ADAMTS13 ACE
29	autosomal dominant polycystic kidney disease	29.4	VEGFA TNF TGFB1 INS CCL2 AGTR1
30	anuria	29.4	NR3C2 F3 AGTR1 ADAMTS13 ACE
31	renal fibrosis	29.2	TNF TGFB1 NR3C2 HIF1A CCN2 CCL2
32	atherosclerosis susceptibility	29.1	VEGFA TNF MTHFR MPO INS F3
33	polycystic kidney disease	29.1	VEGFA TNF TGFB1 INS HIF1A CCL2
34	vascular disease	28.9	VEGFA TNF TGFB1 MTHFR MPO INS
35	liver cirrhosis	28.8	VEGFA TNF TGFB1 INS F3 CCN2
36	kidney disease	28.5	VEGFA TNF TGFB1 NR3C2 NPHS2 NPHS1
37	chronic kidney disease	28.1	VEGFA TNF TGFB1 NR3C2 NPHS2 NPHS1
38	hypertension, essential	28.0	VEGFA TNF TGFB1 NR3C2 NPHS2 NPHS1
39	diabetes mellitus	27.6	VEGFA TNF TGFB1 NR3C2 MTHFR MPO
40	lacrimoauriculodentodigital syndrome	10.9
41	arteritic anterior ischemic optic neuropathy	10.5	MTHFR ACE
42	genetic nephrotic syndrome	10.4	NPHS2 NPHS1
43	fibromuscular dysplasia	10.4	TGFB1 AGTR1 ACE
44	hemifacial spasm	10.4	VEGFA MTHFR
45	multiple cranial nerve palsy	10.4	MPO ACE
46	fuchs' heterochromic uveitis	10.4	CCL2 ACE
47	diffuse scleroderma	10.4	TGFB1 CCN2 ACE
48	urinary tract infection	10.4	TGFB1 ACE
49	diffuse mesangial sclerosis	10.3	TGFB1 NPHS2 NPHS1
50	anterior scleritis	10.3	TNF ACE

Comorbidity relations with Nephrosclerosis via Phenotypic Disease Network (PDN):

Acute Cystitis	Acute Kidney Failure
Deficiency Anemia	Heart Disease
Hydronephrosis	Hypertension, Essential
Kidney Disease	Nephrolithiasis, X-Linked Recessive, with Renal Failure

Graphical network of the top 20 diseases related to Nephrosclerosis:

Sources

Symptoms & Phenotypes for Nephrosclerosis

MGI Mouse Phenotypes related to Nephrosclerosis:

⁴⁶ (show all 15)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	cardiovascular system	MP:0005385	10.42	ACE ACE2 ADRB1 AGTR1 BMP7 CCN2
2	homeostasis/metabolism	MP:0005376	10.41	ACE ACE2 ADAMTS13 ADRB1 AGTR1 CCN2
3	growth/size/body region	MP:0005378	10.39	ACE ACE2 ADRB1 AGTR1 BMP7 CCN2
4	mortality/aging	MP:0010768	10.32	ACE ACE2 ADAMTS13 ADRB1 AGTR1 BMP7
5	hematopoietic system	MP:0005397	10.31	ACE ACE2 ADAMTS13 AGTR1 BMP7 F3
6	immune system	MP:0005387	10.27	ACE ACE2 ADAMTS13 AGTR1 BMP7 CCL2
7	embryo	MP:0005380	10.18	ACE BMP7 CCN2 F3 HIF1A INS
8	digestive/alimentary	MP:0005381	10.14	ACE2 BMP7 CCN2 HIF1A INS TGFB1
9	integument	MP:0010771	10.13	ACE2 BMP7 CCN2 F3 HIF1A INS
10	nervous system	MP:0003631	10.07	ACE AGTR1 BMP7 F3 HIF1A INS
11	muscle	MP:0005369	10.02	ACE2 ADRB1 F3 HIF1A INS MPO
12	liver/biliary system	MP:0005370	10.01	ACE CCN2 HIF1A INS MTHFR TGFB1
13	renal/urinary system	MP:0005367	9.93	ACE ACE2 AGTR1 BMP7 HIF1A INS
14	respiratory system	MP:0005388	9.56	ACE2 BMP7 CCN2 F3 HIF1A TGFB1
15	vision/eye	MP:0005391	9.4	ACE ACE2 ADAMTS13 BMP7 CCN2 F3

Sources

Drugs & Therapeutics for Nephrosclerosis

Drugs for Nephrosclerosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 30)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Angiotensin II

Approved, Investigational

Phase 4

68521-88-0, 4474-91-3, 11128-99-7

172198

Synonyms:

1-8-Angiotensin I

1-L-Aspasaginyl-5-L-valyl angiotensin octapeptide

5 L Isoleucine angiotensin II

5-isoleucine-angiotensin II

5-Isoleucine-angiotensin II

5-L-Isoleucine angiotensin II

5-L-isoleucineangiotensin II

5-L-Isoleucineangiotensin II

Ang II

ANG-(1-8)octapeptide

Angiotensin

Angiotensin 2

Angiotensin II

Angiotensin II (human)

Angiotensin II (mouse)

Angiotensin II, 5-L-isoleucine

Angiotensin-(1-8) octapeptide

Angiotonin

Asp-arg-val-tyr-ile-his-pro-phe

Delivert

Human angiotensin II

Hypertensin

II, 5-L-isoleucine angiotensin

Ile(5)-angiotensin II

Ile5-angiotensin II

Isoleucine(5)-angiotensin

Isoleucine(5)-angiotensin II

isoleucine5-angiotensin II

Isoleucyl(5)-angiotensin II

N-(1-(N-(N-(N-(N-(N(2)-L-a-Aspartyl-L-arginyl)-L-valyl)-L-tyrosyl)-L-isoleucyl)-L-histidyl)-L-prolyl)-L-phenylalanine

N-(1-(N-(N-(N-(N-(N(2)-L-alpha-Aspartyl-L-arginyl)-L-valyl)-L-tyrosyl)-L-isoleucyl)-L-histidyl)-L-prolyl)-L-phenylalanine

N-(1-(N-(N-(N-(N-(N(2)-L-Α-aspartyl-L-arginyl)-L-valyl)-L-tyrosyl)-L-isoleucyl)-L-histidyl)-L-prolyl)-L-phenylalanine

Valyl(5)-angiotensin II

Valsartan

Approved, Investigational

Phase 4

137862-53-4

60846

Synonyms:

(2S)-3-methyl-2-[pentanoyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid

(s)-2-(n-((2'-(1h-tetrazol-5-yl)biphenyl-4-yl)methyl)pentanamido)-3-methylbutanoic acid

(S)-N-valeryl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]-methyl}-valine

(S)-N-Valeryl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]-methyl}-valine

|Tareg

137862-53-4

AC1L1U1M

AC1Q5QIK

AC-4543

Ambap137862-53-4

Aventis brand of valsartan

BIDD:GT0345

Bio-0796

BRD-K45158365-001-02-3

BSPBio_003501

C081489

C24H29N5O3

CEPA brand of valsartan

CGP 48933

CGP-48933

CHEBI:9927

CHEMBL1069

CID60846

CPD000466318

D00400

DB00177

Diovan

Diovan (TN)

Diovan, Valsartan

Esteve brand of valsartan

HMS1922L21

HMS2051L12

HMS2093K22

HSDB 7519

Kalpress

KBio2_002287

KBio2_004855

KBio2_007423

KBio3_003006

KBioGR_001078

KBioSS_002289

Lacer brand of valsartan

LS-161334

L-Valine, N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9CI)

Miten

MLS000759423

MLS001424088

MolPort-002-507-854

MolPort-003-666-608

N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-L-valine

N-(p-(o-1H-Tetrazol-5-ylphenyl)benzyl)-N-valeryl-L-valine

N-(p-(O-1H-Tetrazol-5-ylphenyl)benzyl)-N-valeryl-L-valine

N-(P-(O-1H-Tetrazol-5-ylphenyl)benzyl)-N-valeryl-L-valine

Nisis

Nisis||

Novartis brand of valsartan

N-pentanoyl-N-{[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-L-valine

N-pentanoyl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-L-valine

N-Pentanoyl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-L-valine

N-valeryl-N-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)valine

N-Valeryl-N-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)valine

Provas

S1894_Selleck

SAM001246581

Sanol brand of valsartan

Schwarz brand of valsartan

SMR000466318

SPBio_001260

Spectrum_001796

SPECTRUM1505209

Spectrum2_001120

Spectrum3_001831

Spectrum4_000749

Spectrum5_001582

Tareg

TL8000869

UNII-80M03YXJ7I

Vals

Valsarran

valsartan

Valsartan

Valsartan (JAN/USAN/INN)

Valsartan [USAN:INN]

walsartan

Antihypertensive Agents

Phase 4

Angiotensin Receptor Antagonists

Phase 4

Giapreza

Phase 4

Angiotensin II Type 1 Receptor Blockers

Phase 4

Angiotensinogen

Phase 4

Amlodipine

Approved

Phase 3

88150-42-9

2162

Synonyms:

()-Amlodipine

(RS)-3-ethyl 5-methyl 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate

2-[(2-Aminoethoxy)methyl]-4-(2-chlorophenyl)

-3-(ethoxycarbonyl)-5-(methoxycarbonyl)-6-methyl-1,4-dihydropyridine

3,5-Pyridinedicarboxylic acid, 2-((2-aminoethoxy)methyl)-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester

3,5-Pyridinedicarboxylic acid, 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester

3-ethyl 5-methyl 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate

3-ethyl 5-methyl 2-{[(2-aminoethyl)oxy]methyl}-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate

3-Ethyl 5-methylester, (±)-2-[(2-aminoethoxy)methyl]-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate

3-Ethyl-5-methyl ( -)-2-((2-aminoethoxy)methyl)-4-(2-chlorphenyl)-1,4-dihydro-6-methyl-3,5-pyridindicarboxylat

3-Ethyl-5-methyl ( -)-2-((2-aminoethoxymethyl)-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate

3-Ethyl-5-methyl (.+/-.)-2-[(2-aminoethoxy)methyl]-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate

3-Ethyl-5-methyl (+-)-2-(2-aminoethoxymethyl)-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate

3-Ethyl-5-methyl (+-)-2-(2-aminoethoxymethyl)-4-(O-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate

3-Ethyl-5-methyl (+-)-2-(2-aminoethoxymethyl)-4-(O-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylic acid

3-O-ethyl 5-O-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate

88150-42-9

88150-47-4 (maleate (1:1))

AC1L1D26

AC1Q32ZS

AC-4535

Almirall brand OF amlodipine besilate

Ambap88150-42-9

Amlocard

amlodipine

Amlodipine

Amlodipine (INN)

Amlodipine [INN:BAN]

AMLODIPINE BASE

Amlodipine Benzenesulfonate

Amlodipine besilate

Amlodipine Besilate

Amlodipine besylate

Amlodipine Besylate

Amlodipine free base

Amlodipine Free Base

Amlodipine maleate

Amlodipine maleate (1:1)

Amlodipine, (+-)-isomer

Amlodipine, (+-)-isomer, maleate (1:1)

Amlodipine, (R)-isomer

Amlodipine, (S)-isomer, maleate (1:1)

Amlodipino

Amlodipino [Spanish]

Amlodipinum

Amlodipinum [Latin]

Amlodis

Amlopres

Amlor

Amvaz

AMVAZ

Astudal

BIDD:GT0810

BRD-A22032524-074-02-4

BRD-A22032524-074-03-2

BSPBio_002727

C06825

CHEBI:2668

CHEMBL1491

CID2162

Coroval

CPD000469198

D07450

DB00381

Eczacibasi brand OF amlodipine besilate

HMS2052N03

HMS2089H07

I14-0798

Intervask

Istin

KBio3_001947

KBioGR_001643

Lipinox

Lotrel

LS-131183

Mack brand OF amlodipine besilate

MLS001401409

MolPort-001-792-963

NCGC00165957-01

NCGC00165957-02

NCGC00165957-03

Norvasc

Norvasc (TN)

Pelmec

Pfizer brand OF amlodipine besilate

R,S)-Amlodipine

Racemic amlodipine

Racemic Amlodipine

SAM001246705

SMR000469198

SPBio_000351

Spectrum2_000486

Spectrum3_001004

Spectrum4_001132

Spectrum5_001550

UK-4834011

UNII-1J444QC288

Ramipril

Approved

Phase 3

87333-19-5

5362129

Synonyms:

(2 S ,3 aS ,6 aS )-1[( S )-N-[( S )-1-Carboxy-3-phenylpropyl] alanyl] octahydrocyclopenta [ b ]pyrrole-2-carboxylic acid, 1-ethyl ester

(2S-(1(R*(r*)),2a,3abeta,6abeta))-1-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydrocyclopenta(b)pyrrole-2-carboxylate

(2S-(1(R*(r*)),2a,3abeta,6abeta))-1-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid

(2S-(1(R*(r*)),2alpha,3abeta,6abeta))-1-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydrocyclopenta(b)pyrrole-2-carboxylate

(2S-(1(R*(r*)),2alpha,3abeta,6abeta))-1-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid

(2S-(1(R*(R*)),2alpha,3abeta,6abeta))-1-(2-((1-(Ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid

(2S-(1(R*(R*)),2alpha,3abeta,6abeta))-1-(2-((1-(Ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid.

(2S-(1(R*(r*)),2α,3abeta,6abeta))-1-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydrocyclopenta(b)pyrrole-2-carboxylate

(2S-(1(R*(r*)),2α,3abeta,6abeta))-1-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid

(2S,3aS,6aS)-1-((S)-2-((S)-1-ethoxy-1-oxo-4-phenylbutan-2-ylamino)propanoyl) octahydrocyclopenta[b]pyrrole-2-carboxylic acid

(2s,3as,6as)-1-((s)-2-((s)-1-ethoxy-1-oxo-4-phenylbutan-2-ylamino)propanoyl)-octahydrocyclopenta[b]p

(2s,3as,6as)-1((s)-n-((s)-1-carboxy-3-phenylpropyl)alanyl)octahydrocyclopenta(b)pyrrole-2-carboxylic

(2S,3aS,6aS)-1-((S)-N-((S)-1-Carboxy-3-phenylpropyl)alanyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid, 1-ethyl ester

(2S,3aS,6aS)-1-((S)-N-((S)-1-Ethoxycarbonyl-3-phenylpropyl)alanyl)octahydrocyclopenta(b)pyrrol-2-carbonsaeure

(2S,3aS,6aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-3,3a,4,5,6,6a-hexahydro-2H-cyclopenta[b]pyrrole-2-carboxylic acid

(2S,3aS,6aS)-1-[(2S)-2-{[(1S)-1-ethoxycarbonyl-3-phenylpropyl]amino}propanoyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid

(2S,3aS,6aS)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid (non-preferred name)

(2s,3as,6as)-1-[(s)-2-((s)-1-ethoxycarbonyl-3-phenyl-propylamino)-propionyl]-octahydro-cyclopenta[b]

[2s,3as,6as]-1-[(2s)-2-[[(1s)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydrocyclopen

[2S,3aS,6aS]-1-[(2S)-2-[[(1S)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid

126613-39-6

87333-19-5

AC-1347

AC1NSFPR

Acovil

Almirall brand OF ramipril

Almirall Brand of Ramipril

Altace

Altace (TN)

Astra brand OF ramipril

Astra Brand of Ramipril

AstraZeneca brand OF ramipril

AstraZeneca Brand of Ramipril

Aventis brand OF ramipril

Aventis Brand of Ramipril

Aventis pharma brand OF ramipril

Aventis Pharma Brand of Ramipril

BIDD:GT0803

Bio-0651

BSPBio_003347

C23H32N2O5

Carasel

Cardace

CHEBI:289203

CHEBI:8774

CHEMBL1168

CID5362129

CPD000466386

D00421

D017257

DB00178

Delix

HMS2051E04

HMS2090L11

HMS2093M10

HOE 498

Hoe-498

HOE498

HOE-498

Hoechst brand OF ramipril

Hoechst Brand of Ramipril

Hypren

Hytren

KBio2_002504

KBio2_005072

KBio2_007640

KBio3_002849

KBioGR_001858

KBioSS_002512

Lostapres

LS-58199

MLS000759523

MLS001216547

MLS001423965

MolPort-001-736-571

Monarch brand OF ramipril

Monarch Brand of Ramipril

N-(1S-carboethoxy-3-phenylpropyl)-S-alanyl-cis,endo-2-azabicyclo[3.3.0]octane-3S-carboxylic Acid

Naprix

NCGC00178127-01

Pramace

Pramace (discontinued)

Promed brand OF ramipril

Promed Brand of Ramipril

Quark

R0404_SIGMA

Ramace

ramipril

Ramipril

Ramipril (USP/INN)

Ramipril [USAN:INN:BAN]

Ramiprilum

Ramiprilum [Latin]

Ramipro, Tritace, Altace, Prilace, Ramipril

S1793_Selleck

SAM001246757

SAM002699899

SMR000466386

Spectrum_001958

SPECTRUM1505214

Spectrum3_001794

Spectrum4_001269

Spectrum5_001721

STK801937

Triatec

Tritace

UNII-L35JN3I7SJ

Unipril

Vesdil

Zabien

Metoprolol

Approved, Investigational

Phase 3

51384-51-1, 37350-58-6

4171

Synonyms:

(+/-)-metoprolol

(RS)-Metoprolol

1-(Isopropylamino)-3-(4-(2-methoxyethyl)phenoxy)propan-2-ol

1-(Isopropylamino)-3-(p-(2-methoxyethyl)phenoxy)-2-propanol

1-(isopropylamino)-3-[4-(2-methoxyethyl)phenoxy]propan-2-ol

1-(Isopropylamino)-3-[4-(2-methoxyethyl)phenoxy]propan-2-ol

1-[(1-methylethyl)amino]-3-({4-[2-(methyloxy)ethyl]phenyl}oxy)propan-2-ol

1-[4-(2-methoxyethyl)phenoxy]-3-(propan-2-ylamino)propan-2-ol

1-[4-(2-methoxyethyl)phenoxy]-3-propan-2-ylamino-propan-2-ol

3-[4-(2-methoxyethyl)phenoxy]-1-(propan-2-ylamino)propan-2-ol

37350-58-6

51384-51-1

54163-88-1

AB00053499

AC-19022

AC1L1HKM

AstraZeneca Brand of Metaoprolol Tartrate

AstraZeneca Brand of Seloken

Beatrolol

Beloc

Beloc duriles

Beloc Duriles

Beloc-duriles

BelocDuriles

Beloc-Duriles

Betaloc

Betaloc astra

Betaloc Astra

Betaloc-astra

BetalocAstra

Betaloc-Astra

Betalok

BRD-A03623303-045-02-0

C07202

CCRIS 4198

CGP 2175

CGP2175

CGP-2175

CHEBI:6904

CHEMBL13

CID4171

CR-XL, Metoprolol

D008790

D02358

DB00264

dl-Metoprolol

DL-metoprolol

DL-Metoprolol

Dutoprol

EINECS 253-483-7

EINECS 257-166-4

H 93 26

H 9326

H 93-26

HMS2090B15

HSDB 6531

I01-7125

I06-0125

Jsp006606

L000669

Leiras Brand of Metoprolol Succinate or Metoprolol Tartrate

Lopresor

Lopresoretic

LOPRESSIDONE

Lopressor

Lopressor HCT

LS-122450

Meijoprolol

Metohexal

metoprolol

Metoprolol

Metoprolol (USAN/INN)

Metoprolol [USAN:INN:BAN]

Metoprolol CR XL

Metoprolol CR-XL

Metoprolol succinate

Metoprolol tartrate

Metoprolol Tartrate

Metoprololum

Metoprololum [INN-Latin]

Metroprolol

MolPort-005-938-039

NCGC00021148-02

NCGC00021148-03

NCGC00021148-04

Novartis Brand of Metprolol Tartrate

Preblok

Prelis

Presolol

Seloken

Seloken AstraZeneca Brand

Selopral

Selo-Zok

Seroken

Spesicor

Spesikor

Succinate, metoprolol

Tartrate, metoprolol

Tartrate, Metoprolol

Toprol

Toprol XL

ToprolXL

Toprol-XL

TOPROL-XL

UNII-GEB06NHM23

Epoprostenol

Approved

Phase 2, Phase 3

61849-14-7, 35121-78-9

5280427 5282411

Synonyms:

(5E)-5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(E,3R)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid

(5Z)-5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid

(5Z)-5-[(4R,5R)-5-hydroxy-4-[(E,3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid

(5Z,13E)-(15S)-6,9a-Epoxy-11a,15-dihydroxyprosta-5,13-dienoate

(5Z,13E)-(15S)-6,9a-Epoxy-11a,15-dihydroxyprosta-5,13-dienoic acid

(5Z,13E)-(15S)-6,9alpha-Epoxy-11alpha,15-dihydroxyprosta-5,13-dienoate

(5Z,13E)-(15S)-6,9-alpha-Epoxy-11-alpha,15-dihydroxyprosta-5,13-dienoate

(5Z,13E)-(15S)-6,9alpha-Epoxy-11alpha,15-dihydroxyprosta-5,13-dienoic acid

(5Z,13E)-(15S)-6,9-alpha-Epoxy-11-alpha,15-dihydroxyprosta-5,13-dienoic acid

(5Z,13E)-(15S)-6,9-Epoxy-11,15-dihydroxyprosta-5,13-dienoate

(5Z,13E)-(15S)-6,9-Epoxy-11,15-dihydroxyprosta-5,13-dienoic acid

(5Z,13E)-(15S)-6,9Α-epoxy-11α,15-dihydroxyprosta-5,13-dienoate

(5Z,13E)-(15S)-6,9Α-epoxy-11α,15-dihydroxyprosta-5,13-dienoic acid

(5Z,13E,15S)-6,9a-Epoxy-11a,15-dihydroxyprosta-5,13-dienoate

(5Z,13E,15S)-6,9a-Epoxy-11a,15-dihydroxyprosta-5,13-dienoic acid

(5Z,13E,15S)-6,9alpha-epoxy-11alpha,15-dihydroxyprosta-5,13-dienoic acid

(5Z,9a,11a,13E,15S)-6,9-Epoxy-11,15-dihydroxyprosta-5,13-dien-1-Oate

(5Z,9a,11a,13E,15S)-6,9-Epoxy-11,15-dihydroxyprosta-5,13-dien-1-Oic acid

(5Z,9alpha,11alpha,13E,15S)-11,15-dihydroxy-6,9-epoxyprosta-5,13-dien-1-oic acid

(5Z,9alpha,11alpha,13E,15S)-6,9-Epoxy-11,15-dihydroxyprosta-5,13-dien-1-Oate

(5Z,9alpha,11alpha,13E,15S)-6,9-epoxy-11,15-dihydroxyprosta-5,13-dien-1-oic acid

(5Z,9alpha,11alpha,13E,15S)-6,9-Epoxy-11,15-dihydroxyprosta-5,13-dien-1-Oic acid

(5Z,9Α,11α,13E,15S)-6,9-epoxy-11,15-dihydroxyprosta-5,13-dien-1-Oate

(5Z,9α,11α,13E,15S)-6,9-epoxy-11,15-dihydroxyprosta-5,13-dien-1-oic acid

(5Z,9Α,11α,13E,15S)-6,9-epoxy-11,15-dihydroxyprosta-5,13-dien-1-Oic acid

(Z)-(3aR,4R,5R,6aS)-Hexahydro-5-hydroxy-4-((E)-(3S)-3-hydroxy-1-octenyl)-2H-cyclopenta(b)furan-delta(sup 2,delta)-valeric acid

136626-78-3

35121-78-9

5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid

5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid

5-[5-hydroxy-4-(3-hydroxyoct-1-enyl)-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid

6,9-alpha-Epoxy-11-alpha,15(S)-dihydroxyprosta-5(Z),13(E)-dien-1-oic acid

61849-14-7

63748-50-5

63859-31-4

AC1L18LX

AC1L3FZB

AC1NQX0K

AC1NR00P

AC1O51WG

AC1O5HI7

AR-1I7150

BIDD:GT0514

Bio2_000216

Bio2_000696

BRD-K64054020-001-02-7

BRN 1690090

BSPBio_001496

C01312

CHEBI:15552

CHEMBL1139

CHEMBL307845

CID114805

CID11969614

CID159

CID5280427

CID5282411

CID6434194

CID6450541

CID9864371

CID9975312

D00106

DB01240

Epoprostanol

epoprostenol

Epoprostenol

Epoprostenol (TN)

Epoprostenol (USAN/INN)

Epoprostenol [USAN:INN]

Epoprostenol sodium

Epoprostenol sodium salt, (5Z,9alpha,11alpha,13E,15S)-isomer

Epoprostenolum

Epoprostenolum [INN-Latin]

Flolan

HMS1791K18

HMS1989K18

IDI1_033966

KBio2_000216

KBio2_002784

KBio2_005352

KBio3_000431

KBio3_000432

KBioGR_000216

KBioSS_000216

KB-IV-24

LMFA03010087

LS-125828

NCGC00161285-01

NCGC00161285-02

NCGC00161285-03

PDSP1_001721

PDSP2_001704

PGI(sub 2)

PGI2

PG-I2

PGX

prostacyclin

Prostacyclin

Prostacyclin I2

Prostacycline

Prostacyclins

Prostaglandin I

Prostaglandin I(2)

prostaglandin I2

Prostaglandin I2

Prostaglandin X

Prostaglandins X

SMP2_000227

TRY 200

Try-200

U 53,217

U-53217

UNII-DCR9Z582X0

Vasocyclin

Tezosentan

Investigational

Phase 2, Phase 3

180384-57-0

Beraprost

Investigational

Phase 2, Phase 3

88430-50-6

Angiotensin-Converting Enzyme Inhibitors

Phase 3

Adrenergic Antagonists

Phase 3

Sympatholytics

Phase 3

Adrenergic beta-Antagonists

Phase 3

1,4-dihydropyridine

Phase 3

Adrenergic beta-1 Receptor Antagonists

Phase 3

Adrenergic Agents

Phase 3

Neurotransmitter Agents

Phase 3

Hormones

Phase 3

Calcium, Dietary

Phase 3

HIV Protease Inhibitors

Phase 3

Vasodilator Agents

Phase 3

protease inhibitors

Phase 3

calcium channel blockers

Phase 3

Anti-Arrhythmia Agents

Phase 3

Platelet Aggregation Inhibitors

Phase 2, Phase 3

Calcium

Nutraceutical

Phase 3

7440-70-2

271

Synonyms:

Ca(2+)

Ca2+

Calcio

Calcium

Calcium element

CALCIUM ion

Calcium(2+)

Calcium, doubly charged positive ion

Calcium, elemental

Elemental calcium

Kalzium

Interventional clinical trials:

#	Name	Status	NCT ID	Phase	Drugs
1	Aldosterone Breakthrough During Diovan (Valsartan), Tekturna (Aliskiren), and Combination (Valsartan+Aliskiren) Anti-hypertensive Therapy in Patients With Proteinuric Kidney Disease	Terminated	NCT01129557	Phase 4	Aliskiren;Valsartan
2	African American Study of Kidney Disease and Hypertension	Completed	NCT04364139	Phase 3	Ramipril;Amlodipine;Metoprolol
3	TRK-100STP PhaseIIb/III Clinical Study - Chronic Renal Failure (Primary Glomerular Disease/Nephrosclerosis)	Completed	NCT01090037	Phase 2, Phase 3	TRK-100STP high dose;TRK-100STP low dose;Placebo
4	TRK-100STP PhaseII Clinical Study -Chronic Renal Failure (Primary Glomerular Disease/Nephrosclerosis)	Completed	NCT02480751	Phase 2	Beraprost;Placebo

Search NIH Clinical Center for Nephrosclerosis

Cochrane evidence based reviews: nephrosclerosis

Sources

Genetic Tests for Nephrosclerosis

Sources

Anatomical Context for Nephrosclerosis

MalaCards organs/tissues related to Nephrosclerosis:

⁴⁰

Kidney, Pituitary, Endothelial, Brain, Smooth Muscle, Pancreas, Prostate

Sources

Publications for Nephrosclerosis

Articles related to Nephrosclerosis:

(show top 50) (show all 1441)

#	Title	Authors	PMID	Year
1	[Profibrotic effects of aldosterone]. ⁵⁴ ⁶¹	Van Den Meiracker AH...Boomsma F	15366722	2004
2	Collagen I upregulates extracellular matrix gene expression and secretion of TGF-beta 1 by cultured human mesangial cells. ⁵⁴ ⁶¹	Ortega-Velazquez R...Rodriguez-Puyol D	14761892	2004
3	ACE inhibition is effective and renoprotective in hypertensive nephrosclerosis: the African American Study of Kidney Disease and Hypertension (AASK) trial. ⁵⁴ ⁶¹	Douglas JG...Agodoa L	12864879	2003
4	[Nephropathy associated with arterial hypertension: genes and Barker's hypothesis]. ⁶¹ ⁵⁴	Zoccali C	12439839	2002
5	ACE inhibitors and appearance of renal events in hypertensive nephrosclerosis. ⁵⁴ ⁶¹	Segura J...Ruilope LM	11566948	2001
6	Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. ⁶¹ ⁵⁴	Ruggenenti P...Remuzzi G	10845831	2000
7	Hypertension-induced organ damage in African Americans: transforming growth factor-beta(1) excess as a mechanism for increased prevalence. ⁵⁴ ⁶¹	August P...Suthanthiran M	10981147	2000
8	1,25-dihydroxyvitamin D3 stimulates transforming growth factor-beta1 synthesis by mouse renal proximal tubular cells. ⁵⁴ ⁶¹	Weinreich T...Binswanger U	10394107	1999
9	Effects of quinapril hydrochloride in patients with essential hypertension and impaired renal function. ⁶¹ ⁵⁴	Owada A...Tomita K	9140710	1997
10	Short-term effects of blood pressure control and antihypertensive drug regimen on glomerular filtration rate: the African-American Study of Kidney Disease and Hypertension Pilot Study. ⁶¹ ⁵⁴	Hall WD...Massry SG	9159306	1997
11	Significance of increased accumulation of type VI collagen and transforming growth factor beta 1 in tubulointerstitial damage in hypertensive nephrosclerosis: an immunohistochemical study. ⁵⁴ ⁶¹	Razzaque MS...Taguchi T	8737230	1996
12	Reversible renal insufficiency due to angiotensin converting enzyme inhibitors in hypertensive nephrosclerosis. ⁶¹ ⁵⁴	Toto RD...Pettinger WA	1883120	1991
13	Clinical Outcomes after Endovascular Therapy Among Hemodialysis Patients with Peripheral Artery Disease Stratified by the Primary Kidney Disease. ⁶¹	Iiya M...Sasano T	33418070	2021
14	Hypertensive nephrosclerosis: wider kidney biopsy indications may be needed to improve diagnostics. ⁶¹	Hallan SI...Ix JH	32613703	2021
15	Kidney microRNA-21 Expression and Kidney Function in IgA Nephropathy. ⁶¹	Szeto CC...Lai FM	33604541	2021
16	Association between thrombotic microangiopathy and activated alternative complement pathway in malignant nephrosclerosis. ⁶¹	Zhang Y...Xing G	33367879	2020
17	Prostacyclin analogue beraprost sodium efficacy in primary glomerular disease or nephrosclerosis: Analysis of the Japanese subgroup in CASSIOPEIR Study. ⁶¹	Kurumatani H...Nakamoto H	33340238	2020
18	Nephronophthisis in Young Adults Phenocopying Thrombotic Microangiopathy and Severe Nephrosclerosis. ⁶¹	Doreille A...Mesnard L	33268504	2020
19	[Very-old deceased donors in kidney transplantation: How far can we go?] ⁶¹	Maanaoui M...Hazzan M	33203614	2020
20	Larger Nephron Size and Nephrosclerosis Predict Progressive CKD and Mortality after Radical Nephrectomy for Tumor and Independent of Kidney Function. ⁶¹	Denic A...Rule AD	32938650	2020
21	Peritubular Capillary Rarefaction: An Underappreciated Regulator of CKD Progression. ⁶¹	Kida Y	33158122	2020
22	Ameliorative effect of phosphodiesterase 4 and 5 inhibitors in deoxycorticosterone acetate-salt hypertensive uni-nephrectomized KKAy mice. ⁶¹	Nio Y...Matsuo T	32939821	2020
23	Senior-Løken syndrome misdiagnosed as nephrosclerosis related to hypertensive disorders of pregnancy. ⁶¹	Hirai Y...Uzu T	33109693	2020
24	Progressive Nephron Loss in Aging Kidneys: Clinical-Structural Associations Investigated by Two Anatomical Methods. ⁶¹	Hughson MD...Bertram JF	31599090	2020
25	Chronic kidney disease caused by maternally inherited diabetes and deafness: a case report. ⁶¹	Tanaka K...Masaki T	33125665	2020
26	Performance of the Kidney Failure Risk Equation by Disease Etiology in Advanced CKD. ⁶¹	Hundemer GL...Akbari A	32928746	2020
27	Postoperative complications and perioperative management in patients on hemodialysis undergoing lung resection. ⁶¹	Watanabe Y...Suzuki K	32989668	2020
28	Current findings of kidney biopsy including nephropathy associated with hypertension and diabetes mellitus in Korea. ⁶¹	Kim K...Korean GlomeruloNEphritis sTudy (KoGNET) Group	32784355	2020
29	Immune checkpoint inhibitor therapy-associated graft intolerance syndrome in a failed kidney transplant recipient. ⁶¹	Mejia CD...Yadav A	32976688	2020
30	Stimulation of Structural and Functional Recovery of the Kidney in Rats with Postischemic Acute Renal Failure of Different Severity by Embryonic Protein-Peptide Complex Therapy. ⁶¹	Kirpatovskii VI...Samoilova SI	32990849	2020
31	Time-averaged proteinuria during follow-up and renal prognosis in patients with biopsy-proven benign nephrosclerosis. ⁶¹	Amano H...Yokoo T	32274596	2020
32	Hypertensive nephropathy: a major roadblock hindering the advance of precision nephrology. ⁶¹	Carriazo S...Ortiz A	32897275	2020
33	Pharmacokinetics of dasatinib in a hemodialysis patient with chronic myeloid leukemia and chronic kidney disease. ⁶¹	Mori J...Takahashi N	32152879	2020
34	Endogenous miR-204 Protects the Kidney against Chronic Injury in Hypertension and Diabetes. ⁶¹	Cheng Y...Liang M	32487559	2020
35	Gerontolizing Nephrology: Spectrum of Histopathological Findings of Kidney Biopsy in the Elderly. ⁶¹	Beniwal P...Sharma S	33273792	2020
36	Clinical impact of urinary CD11b and CD163 on the renal outcomes of anti-neutrophil cytoplasmic antibody-associated glomerulonephritis. ⁶¹	Yokoe Y...Matsuo S	32639002	2020
37	The role of complement in arterial hypertension and hypertensive end organ damage. ⁶¹	Wenzel UO...Bode M	32585035	2020
38	Clinical value of multiorgan damage in hypertensive crises: A prospective follow-up study. ⁶¹	Ma H...Zhang W	32271999	2020
39	Correlations Between Interleukin-11 Expression and Hypertensive Kidney Injury in a Rat Model of Renovascular Hypertension. ⁶¹	Menendez-Castro C...Hilgers KF	31840157	2020
40	Current Trends on Glomerulosclerosis Regression. ⁶¹	Stoian M...Stoica V	32728402	2020
41	Premature vascular disease in young adult stroke: a pathology-based case series. ⁶¹	Pasi M...Singhal AB	31853711	2020
42	Mortality patterns in patients with diabetes mellitus at a Nigerian tertiary hospital: A 10-Year autopsy study. ⁶¹	Omenai SA...Ajani MA	32295937	2020
43	Clinical Phenotypes and Long-term Prognosis in White Patients With Biopsy-Verified Hypertensive Nephrosclerosis. ⁶¹	Ovrehus MA...Hallan SI	32154455	2020
44	Pathogenesis of Fabry nephropathy: The pathways leading to fibrosis. ⁶¹	Rozenfeld PA...Bondar C	31718986	2020
45	Efficacy of mesenchymal stem cells in animal models of lupus nephritis: a meta-analysis. ⁶¹	Zhou T...Zhong H	32019582	2020
46	Kidney Structural Features from Living Donors Predict Graft Failure in the Recipient. ⁶¹	Issa N...Rule AD	31974271	2020
47	Re: Larger Nephron Size, Low Nephron Number, and Nephrosclerosis on Biopsy as Predictors of Kidney Function after Donating a Kidney. ⁶¹	Goldfarb DA	31671017	2020
48	Effects of Sustained-Release Beraprost in Patients With Primary Glomerular Disease or Nephrosclerosis: CASSIOPEIR Study Results. ⁶¹	Nakamoto H...Fujita T	31119846	2020
49	[A case of oldest-old patient with chronic renal failure successfully treated with peritoneal dialysis]. ⁶¹	Fujioka H...Kinugawa K	32893214	2020
50	Cardiovascular System Affection and Its Relation to First-Year Mortality in Patients Initiating Maintenance Hemodialysis. ⁶¹	Ali OM...Mohammed RR	32753937	2020

Sources

Genes for Nephrosclerosis

Genes related to Nephrosclerosis (0 elite genes):

(show all 24)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	ACE	Angiotensin I Converting Enzyme	Protein Coding	22.73	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	9140710 1883120 9159306 (more) 11566948 10200812 12864879 10845831 12439839
2	AGTR1	Angiotensin II Receptor Type 1	Protein Coding	19.83	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	11267243
3	TGFB1	Transforming Growth Factor Beta 1	Protein Coding	16.75	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	8737230 10981147 10394107 (more) 14761892
4	NPHS1	NPHS1 Adhesion Molecule, Nephrin	Protein Coding	12.89	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
5	NPHS2	NPHS2 Stomatin Family Member, Podocin	Protein Coding	12.88	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
6	SYNPO	Synaptopodin	Protein Coding	12.45	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
7	CCN2	Cellular Communication Network Factor 2	Protein Coding	12.25	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
8	INS	Insulin	Protein Coding	12.04	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
9	CCL2	C-C Motif Chemokine Ligand 2	Protein Coding	11.92	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
10	ADRB1	Adrenoceptor Beta 1	Protein Coding	11.82	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
11	MPO	Myeloperoxidase	Protein Coding	11.66	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
12	BMP7	Bone Morphogenetic Protein 7	Protein Coding	11.58	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
13	NR3C2	Nuclear Receptor Subfamily 3 Group C Member 2	Protein Coding	11.57	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴	15366722
14	VEGFA	Vascular Endothelial Growth Factor A	Protein Coding	11.52	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
15	ACE2	Angiotensin Converting Enzyme 2	Protein Coding	11.48	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
16	TNF	Tumor Necrosis Factor	Protein Coding	11.45	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
17	MTHFR	Methylenetetrahydrofolate Reductase	Protein Coding	11.28	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
18	ADAMTS13	ADAM Metallopeptidase With Thrombospondin Type 1 Motif 13	Protein Coding	11.2	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
19	HIF1A	Hypoxia Inducible Factor 1 Subunit Alpha	Protein Coding	11.02	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
20	F3	Coagulation Factor III, Tissue Factor	Protein Coding	10.98	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
21	BMP5	Bone Morphogenetic Protein 5	Protein Coding	10.82	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
22	CASP3	Caspase 3	Protein Coding	10.61	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
23	F2	Coagulation Factor II, Thrombin	Protein Coding	10.59	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
24	CYCS	Cytochrome C, Somatic	Protein Coding	10.42	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)

Sources

Variations for Nephrosclerosis

Sources

Expression for Nephrosclerosis

Search GEO for disease gene expression data for Nephrosclerosis.

Sources

Pathways for Nephrosclerosis

Pathways related to Nephrosclerosis according to GeneCards Suite gene sharing:

(show all 24)

#	Super pathways	Score	Top Affiliating Genes
1	TGF-Beta Pathway ⁶³ Show member pathways JAK-STAT Pathway ⁶³ JNK Pathway ⁶³ MAPK Family Pathway ⁶³ Regulation of eIF4 and p70S6K ⁶³ SOCS Pathway ⁶³	13.45	VEGFA TNF TGFB1 INS CCN2 CCL2
2	p70S6K Signaling ⁶³ Show member pathways mTOR Pathway ⁶³ Renin-Angiotensin Pathway ⁶³	12.81	TGFB1 INS HIF1A CCN2 CCL2 BMP7
3	Allograft rejection ³⁶ ¹ Show member pathways Antigen processing and presentation ³⁶ Asthma ³⁶ Autoimmune thyroid disease ³⁶ CTL Mediated Apoptosis ⁶³ Graft-versus-host disease ³⁶ Intestinal immune network for IgA production ³⁶ THC Differentiation Pathway ⁶³ Type I diabetes mellitus ³⁶ Viral myocarditis ³⁶	12.76	VEGFA TNF TGFB1 INS AGTR1
4	Proteoglycans in cancer ³⁶	12.2	VEGFA TNF TGFB1 HIF1A
5	Folate Metabolism ¹ Show member pathways Selenium Micronutrient Network ¹ thioredoxin pathway ¹ Vitamin B12 Metabolism ¹	12.16	TNF MTHFR MPO INS CCL2
6	Dilated cardiomyopathy ³⁶ Show member pathways Hypertrophic cardiomyopathy ³⁶	12.15	TNF TGFB1 ADRB1 ACE
7	Adipogenesis ¹	11.95	TNF TGFB1 INS HIF1A
8	Rheumatoid arthritis ³⁶	11.75	VEGFA TNF TGFB1 CCL2
9	Angiogenesis (CST) ⁴	11.71	TGFB1 HIF1A F3 CCL2
10	Interleukin-4 and 13 signaling ⁶⁵	11.71	VEGFA TNF TGFB1 HIF1A CCL2
11	Renin secretion ³⁶	11.61	AGTR1 ADRB1 ACE
12	Endochondral Ossification ¹	11.58	VEGFA TGFB1 BMP7
13	Primary Focal Segmental Glomerulosclerosis FSGS ¹	11.57	TGFB1 SYNPO NPHS2 NPHS1
14	ACE Inhibitor Pathway, Pharmacodynamics ⁶⁰ Show member pathways ACE Inhibitor Pathway ¹ Agents Acting on the Renin-Angiotensin System Pathway, Pharmacodynamics ⁶⁰ Renin-angiotensin system ³⁶	11.46	TGFB1 NR3C2 AGTR1 ACE2 ACE
15	Hepatitis C and Hepatocellular Carcinoma ¹	11.45	VEGFA TGFB1 HIF1A
16	Malaria ³⁶	11.43	TNF TGFB1 CCL2
17	Differentiation Pathway ¹	11.4	VEGFA TGFB1 INS
18	amb2 Integrin signaling ¹	11.39	TNF MPO CCN2
19	A-beta Pathways: Uptake and Degradation ⁶⁴	11.18	CCL2 ACE2 ACE
20	Lung fibrosis ¹	11.15	TNF TGFB1 CCN2 CCL2 BMP7
21	AGE-RAGE signaling pathway in diabetic complications ³⁶	11.1	VEGFA TNF TGFB1 F3 CCL2 AGTR1
22	G-protein signaling_Rap2B regulation pathway ²³	10.89	TNF TGFB1 CCN2 CCL2 BMP7 ADRB1
23	LDL Oxidation in Atherogenesis ⁶³	10.75	TNF MPO CCL2
24	miR-148a/miR-31/FIH1/HIF1andalpha;-Notch signaling in glioblastoma ¹	10.56	VEGFA HIF1A

Sources

GO Terms for Nephrosclerosis

Cellular components related to Nephrosclerosis according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	extracellular region	GO:0005576	9.73	VEGFA TNF TGFB1 MPO INS F3
2	cell surface	GO:0009986	9.63	VEGFA TNF TGFB1 F3 ADAMTS13 ACE2
3	extracellular space	GO:0005615	9.4	VEGFA TNF TGFB1 MPO INS F3
4	slit diaphragm	GO:0036057	9.26	NPHS2 NPHS1

Biological processes related to Nephrosclerosis according to GeneCards Suite gene sharing:

(show all 44)

#	Name	GO ID	Score	Top Affiliating Genes
1	signal transduction	GO:0007165	10.28	VEGFA NR3C2 INS HIF1A CCN2 CCL2
2	positive regulation of cell migration	GO:0030335	9.99	VEGFA TGFB1 INS F3
3	angiogenesis	GO:0001525	9.98	VEGFA HIF1A CCN2 CCL2
4	positive regulation of protein phosphorylation	GO:0001934	9.96	VEGFA TNF TGFB1 CCN2
5	response to hypoxia	GO:0001666	9.93	VEGFA TGFB1 MTHFR HIF1A
6	kidney development	GO:0001822	9.86	VEGFA BMP7 AGTR1 ACE
7	positive regulation of endothelial cell proliferation	GO:0001938	9.85	VEGFA HIF1A F3
8	cellular response to organic cyclic compound	GO:0071407	9.84	TNF TGFB1 CCL2
9	positive regulation of ERK1 and ERK2 cascade	GO:0070374	9.83	VEGFA TNF TGFB1 CCN2 CCL2
10	positive regulation of MAP kinase activity	GO:0043406	9.82	VEGFA TNF TGFB1
11	positive regulation of protein complex assembly	GO:0031334	9.82	VEGFA TNF TGFB1
12	regulation of cell proliferation	GO:0042127	9.8	TNF TGFB1 HIF1A AGTR1 ACE2
13	positive regulation of blood vessel endothelial cell migration	GO:0043536	9.79	VEGFA TGFB1 HIF1A
14	positive regulation of cell differentiation	GO:0045597	9.77	INS CCN2 BMP7
15	epithelial to mesenchymal transition	GO:0001837	9.76	TGFB1 HIF1A BMP7
16	positive regulation of pri-miRNA transcription by RNA polymerase II	GO:1902895	9.75	TNF TGFB1 HIF1A
17	protein kinase B signaling	GO:0043491	9.74	TNF TGFB1 CCL2
18	negative regulation of gene expression	GO:0010629	9.73	VEGFA TNF TGFB1 HIF1A CCN2 ACE
19	positive regulation of protein kinase B signaling	GO:0051897	9.72	VEGFA TNF TGFB1 INS F3
20	lipopolysaccharide-mediated signaling pathway	GO:0031663	9.71	TNF TGFB1 CCL2
21	positive regulation of positive chemotaxis	GO:0050927	9.69	VEGFA F3
22	surfactant homeostasis	GO:0043129	9.69	VEGFA TGFB1
23	angiotensin maturation	GO:0002003	9.69	ACE2 ACE
24	regulation of blood vessel diameter	GO:0097746	9.69	AGTR1 ACE2 ACE
25	negative regulation of production of miRNAs involved in gene silencing by miRNA	GO:1903799	9.68	TNF TGFB1
26	positive regulation of vascular permeability	GO:0043117	9.68	VEGFA TGFB1
27	positive regulation of cardiac muscle contraction	GO:0060452	9.67	CCN2 ACE2
28	positive regulation of nitric-oxide synthase activity	GO:0051000	9.67	TNF INS HIF1A
29	regulation of transmembrane transporter activity	GO:0022898	9.66	INS ACE2
30	salivary gland morphogenesis	GO:0007435	9.66	TGFB1 BMP7
31	vascular endothelial growth factor production	GO:0010573	9.65	TNF HIF1A
32	regulation of vasoconstriction	GO:0019229	9.65	AGTR1 ACE2 ACE
33	positive regulation of mononuclear cell migration	GO:0071677	9.64	TNF TGFB1
34	positive regulation of transcription from RNA polymerase II promoter in response to hypoxia	GO:0061419	9.63	VEGFA HIF1A
35	camera-type eye morphogenesis	GO:0048593	9.63	VEGFA HIF1A BMP7
36	cytokine-mediated signaling pathway	GO:0019221	9.63	VEGFA TNF TGFB1 HIF1A F3 CCL2
37	positive regulation of peptidyl-tyrosine autophosphorylation	GO:1900086	9.61	VEGFA ACE
38	connective tissue development	GO:0061448	9.61	TGFB1 CCN2
39	connective tissue replacement involved in inflammatory response wound healing	GO:0002248	9.6	TGFB1 HIF1A
40	neural fold elevation formation	GO:0021502	9.55	HIF1A BMP7
41	positive regulation of cellular protein metabolic process	GO:0032270	9.54	TGFB1 INS AGTR1
42	mononuclear cell proliferation	GO:0032943	9.52	TGFB1 ACE
43	positive regulation of gene expression	GO:0010628	9.23	VEGFA TNF TGFB1 INS HIF1A F3
44	regulation of systemic arterial blood pressure by renin-angiotensin	GO:0003081	9.13	AGTR1 ACE2 ACE

Molecular functions related to Nephrosclerosis according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	heparin binding	GO:0008201	9.62	VEGFA MPO CCN2 BMP7
2	growth factor activity	GO:0008083	9.56	VEGFA TGFB1 CCN2 BMP7
3	peptidyl-dipeptidase activity	GO:0008241	9.16	ACE2 ACE
4	cytokine activity	GO:0005125	9.02	VEGFA TNF TGFB1 CCL2 BMP7
5	bradykinin receptor binding	GO:0031711	8.96	AGTR1 ACE

Sources

Sources for Nephrosclerosis

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FMA

²⁰ GARD

²¹ GeneAnalytics

²² GeneCards

²³ GeneGo (Thomson Reuters)

²⁴ GeneHancer via GeneCards

²⁵ GeneReviews

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HMDB

³¹ HPO

³² ICD10

³³ ICD10 via Orphanet

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ KEGG

³⁷ LifeMap

³⁸ LncRNADisease

³⁹ LOVD

⁴⁰ MalaCards

⁴¹ MedGen

⁴² MedlinePlus

⁴³ MedlinePlus Genetics

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NINDS

⁵⁴ Novoseek

⁵⁵ Novus Biologicals

⁵⁶ OMIM via Orphanet

⁵⁷ OMIM® (Updated 05-Mar-2021)

⁵⁸ Orphanet

⁵⁹ PathCards

⁶⁰ PharmGKB

⁶¹ PubMed

⁶² PubMed Health

⁶³ QIAGEN

⁶⁴ R&D Systems

⁶⁵ Reactome

⁶⁶ Sino Biological

⁶⁷ SNOMED-CT

⁶⁸ SNOMED-CT via HPO

⁶⁹ TGDB

⁷⁰ Tocris

⁷¹ UMLS

⁷² UMLS via Orphanet

⁷³ UniProtKB/Swiss-Prot

⁷⁴ Wikipedia